Piper downgrades IO Biotech amid strategic alternatives evaluation

1 week ago 8

TipRanks

Tue, January 27, 2026 astatine 7:00 AM CST 1 min read

Piper Sandler Friday nighttime downgraded IO Biotech (IOBT) to Neutral from Overweight with a price target of 50c, down from $3. The steadfast cites the company’s volition to research strategical opportunities to maximize shareholder worth for the downgrade. While the underlying subject down IO’s T-win level and pb campaigner cylembio is promising, the institution continues to look superior constraints, the expert tells investors successful a probe note. Piper stepped to the sidelines, saying there’s nary assurance the company’s strategical alternatives process volition cookware retired favorably, oregon that a transaction volition beryllium completed connected charismatic terms.

Unlock hedge fund-level information and almighty investing tools for smarter, sharper decisions
Stay up of the marketplace with the latest quality and investigation and maximize your portfolio's potential

Published archetypal connected TheFly – the eventual root for real-time, market-moving breaking fiscal news. Try Now>>

See today’s best-performing stocks connected TipRanks >>

Read More connected IOBT:

Disclaimer & DisclosureReport an Issue

IO Biotech downgraded to Neutral from Overweight astatine Piper Sandler
IO Biotech Explores Strategic Alternatives Amid Cost-Cutting Plans
IO Biotech announces exploration of strategical alternatives
IO Biotech downgraded to Underweight from Equal Weight astatine Morgan Stanley
IO Biotech Receives Nasdaq Notice for Bid Price Noncompliance

Read Entire Article